ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,146.86
-0.21%
Dow Jones
38,589.16
-0.15%
Gold vs US Dollar
2,333.015
0.00%
Brent Oil
82.275
0.00%
Bitcoin
66,055.49
0.08%
Pepperstone
Advertisement
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Esperion Therapeutics Inc (ESPR)

  7. Esperion Therapeutics Inc (ESPR) News

Esperion Therapeutics (ESPR)

Esperion Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ESPR
DateTimeSourceHeadlineSymbolCompany
28/05/202421:16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ESPREsperion Therapeutics Inc
24/05/202421:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ESPREsperion Therapeutics Inc
24/05/202421:14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ESPREsperion Therapeutics Inc
24/05/202421:13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ESPREsperion Therapeutics Inc
23/05/202414:00GlobeNewswire Inc.Esperion to Participate in Upcoming June Investor ConferencesNASDAQ:ESPREsperion Therapeutics Inc
22/05/202413:00GlobeNewswire Inc.First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular RiskNASDAQ:ESPREsperion Therapeutics Inc
20/05/202421:14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ESPREsperion Therapeutics Inc
20/05/202411:00GlobeNewswire Inc.Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for HypercholesterolemiaNASDAQ:ESPREsperion Therapeutics Inc
17/05/202420:08Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ESPREsperion Therapeutics Inc
14/05/202413:00GlobeNewswire Inc.Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®NASDAQ:ESPREsperion Therapeutics Inc
10/05/202421:00GlobeNewswire Inc.Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:ESPREsperion Therapeutics Inc
08/05/202421:31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ESPREsperion Therapeutics Inc
07/05/202413:50Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ESPREsperion Therapeutics Inc
07/05/202412:29Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ESPREsperion Therapeutics Inc
07/05/202411:00GlobeNewswire Inc.Esperion Reports First Quarter 2024 Financial ResultsNASDAQ:ESPREsperion Therapeutics Inc
29/04/202413:00GlobeNewswire Inc.Esperion to Participate in Upcoming May Investor ConferencesNASDAQ:ESPREsperion Therapeutics Inc
23/04/202413:00GlobeNewswire Inc.Esperion to Report First Quarter 2024 Financial Results on May 7NASDAQ:ESPREsperion Therapeutics Inc
07/04/202419:45GlobeNewswire Inc.Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with ObesityNASDAQ:ESPREsperion Therapeutics Inc
01/04/202413:00GlobeNewswire Inc.Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024NASDAQ:ESPREsperion Therapeutics Inc
26/03/202412:00GlobeNewswire Inc.Esperion to Participate in 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:ESPREsperion Therapeutics Inc
25/03/202420:00GlobeNewswire Inc.Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24NASDAQ:ESPREsperion Therapeutics Inc
22/03/202422:26Business WireU.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin UseNASDAQ:ESPREsperion Therapeutics Inc
22/03/202419:10GlobeNewswire Inc.U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin UseNASDAQ:ESPREsperion Therapeutics Inc
22/03/202415:04GlobeNewswire Inc.CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular EventsNASDAQ:ESPREsperion Therapeutics Inc
27/02/202414:19Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ESPREsperion Therapeutics Inc
27/02/202412:23Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ESPREsperion Therapeutics Inc
27/02/202411:00GlobeNewswire Inc.Esperion Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:ESPREsperion Therapeutics Inc
16/02/202421:30GlobeNewswire Inc.Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:ESPREsperion Therapeutics Inc
14/02/202419:14Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ESPREsperion Therapeutics Inc
14/02/202415:50Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ESPREsperion Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ESPR

Your Recent History

USOTC
CDSG
China Dongsheng (PK)
USOTC
GRNL
Greenlite Ventures (PK)
LSE
JT13
Ubsetf Jt13
EU
SANNV
Sanofi NV24
TSX
TPU
TD US Equity Index ETF
BIT
UC2XVE
Unicredit Bank
BIT
PRO
Banco Profilo
EU
V159S
V159S
UNSW3
CNTRUSDT
Centaur Token
USOTC
SUPCF
Supalai Public (PK)
LSE
MGAM
Morgan Advanced Materials
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved